Transgenomic to Hold First Quarter Financial Results Conference Call on May 12, 2011

OMAHA, Neb., May 5, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:

To access the call via telephone, call 800-895-0198 from the U.S. or Canada or 785-424-1053 for international participants and enter conference ID TRANS.  A telephone replay will be available from 6:00 p.m. Eastern Time May 12, 2011 through 11:59 p.m. Eastern Time on May 26, 2011 by dialing 800-374-0328 (domestic) or 402-220-0663 (international).

About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Product offerings include the WAVE Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,500 systems have been installed in customers' labs in more than 50 countries. The SURVEYOR Mutation Detection Kits provide reagents and protocols for high sensitivity detection of mutations in DNA. HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic karyotyping and FISH analyses. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials. The Transgenomic Molecular Laboratories specialize in molecular diagnostics for cardiology, neurology, mitochondrial disorders, oncology, hematology, molecular pathology and other inherited diseases. Transgenomic believes there is a significant opportunity to continue growing the demand for its molecular-based testing by leveraging core technologies, experience, and expertise in biomarker analysis. In addition, the company continues to seek out and evaluate new technologies and new tests to extend its offerings in molecular diagnostics and pharmacogenomics services.

SOURCE Transgenomic, Inc.